US 7846908
RNAi modulation of TGF-beta and therapeutic uses thereof
granted A61PA61P1/16A61P43/00
Quick answer
US patent 7846908 (RNAi modulation of TGF-beta and therapeutic uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Dec 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 32
- CPC classes
- A61P, A61P1/16, A61P43/00, A61P9/00